Skip to Main Content
Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascot and catch up on our reading. There is also paperwork to be done and the annual hunt for a trusty shovel hiding in the tool shed. And what about you? This is a fine time to cozy up with a good book or in front of the telly. You could go shopping before prices rise again. Or you could convince someone to get vaccinated. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you Tuesday, since there is an extended break on this side of the pond. …

Desperate to reverse the turmoil surrounding its controversial Alzheimer’s treatment Aduhelm, Biogen (BIIB) has a shopping list of potential acquisitions, STAT reports. And the company’s risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive. The company, whose stock price is down nearly 50% since Aduhelm’s June approval, is working with Goldman Sachs to find potential buyout targets The investment bank has provided Biogen with a list of smaller biotech companies that might fit with the company’s focus on neuroscience, although Biogen has not approached any of the companies about a deal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment